Urogen Pharma (NASDAQ:URGN) General Counsel Jason Drew Smith Sells 1,520 Shares

Key Points

• Jason Drew Smith, General Counsel of Urogen Pharma, sold 1,520 shares at an average price of $19.11, resulting in a 3.39% decrease in his holdings.
• Urogen Pharma reported a quarterly loss of ($1.05) EPS, missing analysts' expectations, despite revenue of $24.22 million.
• Analyst ratings for Urogen Pharma are predominantly positive, with an average price target of $32.00 and some firms maintaining a buy or outperform rating on the stock.

Urogen Pharma (NASDAQ:URGN - Get Free Report) General Counsel Jason Drew Smith sold 1,520 shares of Urogen Pharma stock in a transaction on Monday, September 8th. The stock was sold at an average price of $19.11, for a total transaction of $29,047.20. Following the completion of the sale, the general counsel owned 43,305 shares of the company's stock, valued at approximately $827,558.55. This trade represents a 3.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Jason Drew Smith also recently made the following trade(s):

• On Monday, July 28th, Jason Drew Smith sold 7,522 shares of Urogen Pharma stock. The stock was sold at an average price of $19.14, for a total transaction of $143,971.08.

Urogen Pharma Price Performance

Shares of NASDAQ:URGN traded down $0.73 during midday trading on Tuesday, reaching $20.69. The company had a trading volume of 1,406,924 shares, compared to its average volume of 1,045,916. The stock's fifty day moving average price is $17.85 and its 200-day moving average price is $12.68. The stock has a market capitalization of $957.12 million, a P/E ratio of -6.23 and a beta of 1.10. Urogen Pharma has a one year low of $3.42 and a one year high of $21.71.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.23). The company had revenue of $24.22 million during the quarter, compared to the consensus estimate of $23.06 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%. As a group, sell-side analysts forecast that Urogen Pharma will post -3.12 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have commented on URGN. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 price objective on shares of Urogen Pharma in a report on Tuesday, August 5th. Oppenheimer set a $31.00 price objective on shares of Urogen Pharma and gave the stock a "buy" rating in a report on Friday, June 13th. Scotiabank reaffirmed an "outperform" rating on shares of Urogen Pharma in a report on Friday, June 13th. The Goldman Sachs Group set a $16.00 price objective on shares of Urogen Pharma and gave the stock a "neutral" rating in a report on Friday, June 13th. Finally, Piper Sandler began coverage on shares of Urogen Pharma in a report on Monday, August 18th. They issued an "overweight" rating and a $36.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $32.00.

Institutional Investors Weigh In On Urogen Pharma

Several institutional investors have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Urogen Pharma by 216.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company's stock worth $48,227,000 after purchasing an additional 2,983,368 shares during the period. RTW Investments LP lifted its holdings in Urogen Pharma by 1.3% in the fourth quarter. RTW Investments LP now owns 3,834,794 shares of the company's stock worth $40,841,000 after purchasing an additional 47,447 shares during the period. RA Capital Management L.P. acquired a new stake in Urogen Pharma in the first quarter worth about $35,461,000. Soleus Capital Management L.P. acquired a new stake in Urogen Pharma in the second quarter worth about $29,934,000. Finally, Vestal Point Capital LP lifted its holdings in Urogen Pharma by 32.1% in the first quarter. Vestal Point Capital LP now owns 2,152,957 shares of the company's stock worth $23,812,000 after purchasing an additional 522,957 shares during the period. Institutional investors and hedge funds own 91.29% of the company's stock.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.